Letter by Donzelli et al Regarding Article, “Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)”
- 23 October 2018
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Cardiology
- Vol. 138 (17), 1912-1913
- https://doi.org/10.1161/circulationaha.118.034068
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes MellitusJournal of the American College of Cardiology, 2018
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseJournal of the American College of Cardiology, 2018
- The efficacy of ezetimibe does not seem a credible real effectInternational Journal of Cardiology, 2016
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesThe New England Journal of Medicine, 2015
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJournal of the American College of Cardiology, 2014
- The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsThe Lancet, 2012